Legal Notices

This Web site is provided by Incyte Corporation ("Incyte").

PLEASE READ AND REVIEW THE FOLLOWING TERMS CAREFULLY BEFORE USING THE WEB SITE. The following terms govern your use of the Web site, and by using the Web site you agree to be bound by and to comply with such terms. If you do not agree, you may not access or use the Web site. Incyte reserves the right to modify these terms from time to time without notice.

Use of the Web site
While Incyte uses reasonable efforts to include up-to-date and accurate information on the Web site, INCYTE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ACCURACY, COMPLETENESS OR SUITABILITY OF THE INFORMATION MADE AVAILABLE ON THE WEB SITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE INFORMATION ON THE WEB SITE IS PROVIDED TO YOU AS IS. Incyte disclaims any and all liability related to use of the Web site or any Web site linked to this notice. Incyte shall not have any obligation to update the Web site. Your access and use of the Web site, including without limitation, the information made available on the Web site, is at your own risk. You agree that you will not make any claim against Incyte based on your access or use, or inability to use, the Web site or its contents. Incyte shall not be liable in any manner whatsoever for any direct, indirect, consequential, incidental, special or punitive damages arising out of your access, use or inability to use the Web site or its contents, or errors or omissions in the content thereof, including without limitation, loss of use, data or profits, whether in an action based on contract, negligence or other tort.

The Web site and the information contained or referenced on the Web site is intended for informational, personal and non-commercial purposes only. The Web site does not provide medical or professional services or advice and should not be relied upon as the basis of any healthcare decision. Persons requiring diagnosis or treatment or with questions specific to an individual are urged to contact their healthcare provider.

The Web site is only intended for use by U.S. residents who are at least eighteen (18) years of age. You should not construe anything on the Web site as a promotion of or solicitation for any product or service that is not authorized by the laws and regulations of the jurisdiction in which you are located.

You may not use the Web site or its contents for any purpose that is unlawful.

Copyright and Other Intellectual Property Rights
The Web site, and the information which it contains, is the property of Incyte, and is protected from unauthorized copying and dissemination by United States copyright law, international conventions and other intellectual property laws. The trademarks, service marks, logos, or other intellectual property displayed on the Web site are owned by Incyte except as otherwise noted. Nothing on the Web site should be construed to grant any license or right in or to any trademarks, service mark, logos or other intellectual property rights. All rights are reserved by the owners of each trademark, service mark, logo, or other intellectual property, except as otherwise described in this notice.

Links to Third-Party Web Sites
As a convenience to you, we may provide links to third-party Web sites that may be of interest to you. Such third-party Web sites are subject to their own terms of use. Incyte does not monitor, approve, endorse, warrant or sponsor any information, conclusions, recommendations, products or services described on those Web sites. Incyte shall have no responsibility or liability for your use of or access to such third-party Web sites.

Information Submitted to Incyte
Should you submit any information (e.g. feedback, suggestions, ideas or comments) to Incyte via the Web site, such information, except for personally identifiable information which is covered by Incyte's Privacy Policy, will be deemed to be Incyte's property and non-confidential; and Incyte shall be free to use, reproduce, disseminate, distribute and otherwise exploit such information without limitation, and without providing any compensation to you. Incyte shall be free to use any ideas, concepts, know-how, techniques or methods contained in such information for any purpose, and in any manner, whatsoever. By submitting such information you warrant and represent that you are the owner of all rights in such information. Under no circumstances shall you use the Web site or any of Incyte's email or other addresses to send Incyte proprietary or confidential information belonging to a third party.

Privacy Policy
See Incyte's Privacy Policy for the terms and disclosures relating to the collection and use of your personal information.

No Offer and No Solicitation
The information provided on the Web site does not constitute an, and is not provided in relation to any, offer of or solicitation for the purchase or disposal of, trading or any transaction in any Incyte securities. Investors must not rely on this information when making investment decisions.

Forward-Looking Statements
The Web site may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, except for the historical information contained therein, the matters set forth in Incyte press releases and announcements are also forward-looking statements. These statements relate to future periods, future events or our future operating or financial plans or performance. These statements can often be identified by the use of forward-looking terminology such as “expects,” “believes,” “intends,” “anticipates,” “estimates,” “plans,” “may,” or “will,” or the negative of these terms, and other similar expressions. These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected. For a discussion of some of the factors that may cause results to differ, see Incyte's reports filed with the Securities and Exchange Commission. Incyte disclaims any intent or obligation to update these forward-looking statements. You should not place undue reliance on these forward-looking statements.

Miscellaneous
Incyte reserves the right to change the content of the Web site at any time without notice to you. Incyte reserves the right to terminate your access or use of the Web site at any time. If your violation of these terms causes harm to others, you shall indemnify and hold Incyte harmless from and against any and all liabilities, losses, damage and expenses related thereto. These terms shall be governed by the laws of the State of Delaware, without giving effect to its conflict of laws principles. You hereby submit to the jurisdiction of the state and federal courts in Wilmington, Delaware in any proceeding relating to the Web site or its contents. These terms set forth the entire agreement between you and Incyte with respect to the subject matter hereof.

Copyright Notice Applicable to Web Site
Copyright © 2004 - 2012 Incyte Corporation. All Rights Reserved.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.

IMPORTANT SAFETY INFORMATION

• Treatment with Jakafi can cause hematologic adverse reactions, including thrombocytopenia, anemia and neutropenia, which are each dose-related effects, with the most frequent being thrombocytopenia and anemia. A complete blood count must be performed before initiating therapy with Jakafi. Complete blood counts should be monitored as clinically indicated and dosing adjusted as required
• The three most frequent non-hematologic adverse reactions were bruising, dizziness and headache
• Patients with platelet counts <200 X 109/L at the start of therapy are more likely to develop thrombocytopenia during treatment. Thrombocytopenia was generally reversible and was usually managed by reducing the dose or temporarily withholding Jakafi. If clinically indicated, platelet transfusions may be administered
• Patients developing anemia may require blood transfusions. Dose modifications of Jakafi for patients developing anemia may also be considered
• Neutropenia (ANC <0.5 X 109/L) was generally reversible and was managed by temporarily withholding Jakafi
• Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal and viral infections. Active serious infections should have resolved before starting Jakafi. Physicians should carefully observe patients receiving Jakafi for signs and symptoms of infection (including herpes zoster) and initiate appropriate treatment promptly
• A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or in patients with renal or hepatic impairment [see Dosage and Administration]. Patients should be closely monitored and the dose titrated based on safety and efficacy
• There are no adequate and well-controlled studies of Jakafi in pregnant women. Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus
• Women taking Jakafi should not breast-feed. Discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother

Note: To view or print PDF files, you must have Adobe® Reader®. Download Adobe Reader here.

Adobe® Reader® is a registered trademark of Adobe Systems Incorporated.

By clicking third-party links, you are leaving an Incyte Web site and going to an external, entirely independent third-party Web site. Incyte provides these links as a service to its Web site visitors and users and takes no responsibility for any information presented on such sites or for your use of or access to such sites.